Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bright Minds Biosciences (DRUG)
NASDAQ:DRUG
RESEARCH TOOLSreports
Holding DRUG?
Track your performance easily
DRUG Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.93 - $79.02
Previous Close$32.67
Volume275.11K
Average Volume (3M)3.05M
Market Cap
$258.79M
Enterprise Value$255.36M
Total Cash (Recent Filing)C$6.75M
Total Debt (Recent Filing)C$73.55K
Price to Earnings (P/E)―
Beta6.37
Next Earnings
Mar 11, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding4,463,837
10 Day Avg. Volume209,039
30 Day Avg. Volume3,049,429
Standard Deviation5.96
R-Squared0.00288
Alpha0.94
Financial Highlights & Ratios
Price to Book (P/B)22.07
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bright Minds Biosciences News
PremiumCompany Announcements
Bright Minds Biosciences to Present Novel Epilepsy Data
PremiumCompany Announcements
Bright Minds Biosciences Secures $35 Million Investment
PremiumCompany Announcements
Bright Minds and Firefly Neuroscience Renew Collaboration
PremiumCompany Announcements
Bright Minds Biosciences’ $35M Private Placement BoostOwnership Overview
41.70% Insiders
2.63% Other Institutional Investors
55.67% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DRUG FAQ
What was Bright Minds Biosciences’s price range in the past 12 months?
Bright Minds Biosciences lowest stock price was $0.93 and its highest was $79.02 in the past 12 months.
What is Bright Minds Biosciences’s market cap?
Currently, no data Available
When is Bright Minds Biosciences’s upcoming earnings report date?
Bright Minds Biosciences’s upcoming earnings report date is Mar 11, 2025 which is in 110 days.
How were Bright Minds Biosciences’s earnings last quarter?
Bright Minds Biosciences released its earnings results on Aug 14, 2024. The company reported $0.037 earnings per share for the quarter, beating the consensus estimate of N/A by $0.037.
Is Bright Minds Biosciences overvalued?
According to Wall Street analysts Bright Minds Biosciences’s price is currently Overvalued.
Does Bright Minds Biosciences pay dividends?
Bright Minds Biosciences does not currently pay dividends.
What is Bright Minds Biosciences’s EPS estimate?
Bright Minds Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bright Minds Biosciences have?
Bright Minds Biosciences has 6,948,489 shares outstanding.
What happened to Bright Minds Biosciences’s price movement after its last earnings report?
Bright Minds Biosciences reported an EPS of $0.037 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.98%.
Which hedge fund is a major shareholder of Bright Minds Biosciences?
Currently, no hedge funds are holding shares in DRUG
---
Bright Minds Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DRUG Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth C$1.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2664.11%
12-Months-Change
Fundamentals
Return on Equity
-51.45%
Trailing 12-Months
Asset Growth
-25.80%
Trailing 12-Months
Company Description
Bright Minds Biosciences
Bright Minds Biosciences Inc is a pre-clinical biosciences company. It is is focused on developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders.
---
Technical Analysis
---